SCHEMBL1475660

SCHEMBL1475660

CCOC(=O)C1CC1(CC)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 2/20 0.45
NPSR1 Q6W5P4 1/20 0.43
MAPT P10636 2/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
ATM Q13315 1/20 0.38
SLC6A4 P31645 2/20 0.38
SLC6A3 Q01959 2/20 0.38
KDM1A O60341 2/20 0.38
RCOR1 Q9UKL0 1/20 0.38
MAOA P21397 2/20 0.38
MAOB P27338 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
TSHR P16473 1/20 0.37
MEN1 O00255 1/20 0.37
HSP90AA1 P07900 1/20 0.37
CRHBP P24387 1/20 0.37
KMT2A Q03164 1/20 0.37
CRHR2 Q13324 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1473720 0.83 MAOA (0.41) SLC6A4SLC6A3KDM1ARCOR1MAOA
SCHEMBL1474477 0.83 ALDH1A1 (0.46) ALDH1A1KDM4ENPSR1MAPTPOLB
SCHEMBL11076947 0.82 ADAM17 (0.47) ALDH1A1KDM4ENPSR1MAPTPOLB
SCHEMBL1475756 0.81 ALDH1A1 (0.44) ALDH1A1KDM4ENPSR1MAPTPOLB
SCHEMBL1474012 0.72 RORC (0.41) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL28685852 0.71 OPRM1 (0.56) SLC6A4
SCHEMBL9820733 0.70 MEN1 (0.45) ALDH1A1MAPTPOLBGAASMN1; SMN2
SCHEMBL19385911 0.69 OPRM1 (0.42) ALDH1A1KDM4ENPSR1MAPTGAA
SCHEMBL20657906 0.69 OPRM1 (0.42) ALDH1A1KDM4ENPSR1MAPTGAA
SCHEMBL19403862 0.69 OPRM1 (0.42) ALDH1A1KDM4ENPSR1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1861359-B1 N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN PFIZER (US) 2012-11-14 EP disclosed
US-7915448-B2 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists PFIZER INC. (US) 2011-03-29 US disclosed
US-20100035880-A1 SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS PFIZER INC 2010-02-11 US disclosed
US-7622589-B2 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists PFIZER INC. (US) 2009-11-24 US disclosed
US-20060211741-A1 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists PFIZER, INC. 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211741-A1 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists CNR1, HVCN1, CNR2 ALDH1A1 1314/4885KDM4E 4595/4885NPSR1 116/4885
US-20100035880-A1 SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS CNR1, HVCN1, CNR2 ALDH1A1 1339/4885KDM4E 4651/4885NPSR1 114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.